BridgeBio Oncology Therapeutics, Inc. Expense Related to Distribution or Servicing and Underwriting Fees
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Expense Related to Distribution or Servicing and Underwriting Fees of $1.84 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Operating Expenses
us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees · last filed 2024-05-15
- BridgeBio Oncology Therapeutics, Inc. expense related to distribution or servicing and underwriting fees for the quarter ending 2024-03-31 was $1.84M.
| Period end | Expense Related to Distribution or Servicing and Underwriting Fees 3 month |
|---|---|
| 2024-03-31 | $1.84M 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |